Schrodinger stock (US80655G1067): AI-powered drug discovery story after latest earnings

Schrodinger has reported fresh quarterly figures and updated investors on its AI-driven drug discovery platform. What the latest numbers, the split between software and drug discovery, and recent share price moves mean for US investors.

Schrodinger is drawing fresh attention from investors after releasing its latest quarterly results and updating on its AI-powered drug discovery pipeline, including the performance of its software segment and collaboration revenues, according to a shareholder letter and earnings materials published on 05/08/2025 and 08/08/2024 on the company’s investor relations site and via business media such as Schrodinger IR as of 05/08/2025 and Reuters as of 08/08/2024.

As of: 16.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: SDGR
• Sector/industry: Computational chemistry, life sciences software, biotechnology
• Headquarters/country: New York, United States
• Core markets: Pharma and biotech research, materials science, US and global
• Key revenue drivers: Software licenses and services, drug discovery milestones and collaborations
• Home exchange/listing venue: Nasdaq (ticker: SDGR)
• Trading currency: USD

Schrodinger: core business model

Schrodinger positions itself at the intersection of physics-based computational chemistry, artificial intelligence and drug discovery. The company develops and sells software that helps pharmaceutical, biotechnology and materials science companies design molecules more efficiently, using simulations to predict how potential drugs or materials will behave before they are synthesized in the lab, according to a company description updated on 03/21/2024 on its website Schrodinger website as of 03/21/2024.

The business model is built on two pillars: a recurring software segment and a more volatile but potentially higher-upside drug discovery segment. The software side generates revenue mainly through on-premise and cloud subscriptions, professional services and consulting, while the drug discovery arm aims for milestone payments, potential royalties, and sometimes equity stakes from partnerships with larger pharma groups or internally led programs, as described in the company’s annual report for 2023 published on 02/28/2024 on its investor relations site Schrodinger Form 10-K as of 02/28/2024.

The strategic idea is that improvements to the software platform not only support external customers but also enhance Schrodinger’s own internal pipeline. The company reports that it reinvests a significant portion of gross profit into R&D to expand its platform capabilities and advance early-stage drug candidates, which can increase long-term optionality if compounds progress into clinical phases and attract partners, based on management commentary in the Q4 2024 shareholder letter dated 02/29/2025 on the investor portal Schrodinger IR as of 02/29/2025.

For US investors, Schrodinger’s hybrid structure means the stock can trade more like a high-growth software name in periods where recurring license revenue dominates sentiment, and more like a biotech company during moments when pipeline readouts or collaboration announcements drive the narrative. That dual character can create both diversification inside the business and additional complexity when interpreting quarterly swings in revenue or earnings.

Main revenue and product drivers for Schrodinger

In its financial disclosures, Schrodinger typically breaks out results into software and drug discovery revenue. For the full year 2023, the company reported total revenue of approximately 216 million USD, with software revenue contributing the majority and growing at a double-digit rate year over year, according to the annual filing for 2023 and associated press release dated 02/28/2024 on the company’s IR site Schrodinger IR as of 02/28/2024.

The software platform includes flagship products for molecular modeling and simulation, such as suites that support structure-based drug design, lead optimization and predictive toxicity, alongside tools tailored to materials science applications like polymers and electronic materials. Customers range from large multinational pharmaceutical companies to smaller biotech firms and academic institutions, which typically license the software on an annual or multi-year basis, according to a product overview updated on 09/12/2024 on the company’s website Schrodinger platform page as of 09/12/2024.

On the drug discovery side, Schrodinger pursues a mix of wholly owned and partnered programs. In oncology and immunology, for instance, the company has disclosed preclinical and early clinical candidates developed with the help of its physics-based modeling methods. Some of these projects are run in collaboration with larger pharmaceutical partners, which can provide upfront payments and research funding, and may lead to milestone and royalty income if programs reach later stages, according to pipeline updates in a corporate presentation dated 03/14/2025 on the investor relations portal Schrodinger corporate presentation as of 03/14/2025.

Quarter to quarter, drug discovery revenue can be lumpy, since it depends on the timing of collaboration milestones and license events. In contrast, software revenue tends to be more predictable, driven by customer retention rates, seat expansion and cloud usage. Management has repeatedly emphasized the goal of growing software revenue at a healthy pace while using collaborations to help fund the more capital-intensive aspects of in-house discovery efforts, as mentioned on the Q4 2024 earnings call held on 02/29/2025 and summarized in a financial news report on Bloomberg as of 03/01/2025.

An additional lever for Schrodinger is the expansion of its platform beyond traditional small-molecule drugs. The company has indicated interest in applying its modeling tools to new modalities and to materials science problems, which could broaden the addressable market over time. However, such expansions typically require new R&D investment and may take several years to translate into meaningfully higher revenue, which is a factor investors often monitor when assessing spending levels and operating losses.

Industry trends and competitive position

Schrodinger operates in a competitive market for molecular modeling and AI-driven drug discovery, facing both established software vendors and newer AI-first biotechnology firms. Over the past few years, the broader sector has seen rising interest from large pharma companies seeking to use in silico methods to shorten discovery timelines, reduce late-stage failures and manage R&D budgets more efficiently, as reported in a market overview by a life sciences analytics firm published on 06/17/2024 on S&P Global as of 06/17/2024.

Within this environment, Schrodinger highlights its long history in physics-based modeling, arguing that combining rigorous quantum-mechanical methods with machine learning can provide more accurate predictions than purely data-driven approaches when experimental data is limited. At the same time, competitors are investing heavily in generative models, high-throughput screening platforms and automated labs, which can pressure pricing and require Schrodinger to keep up in areas such as cloud scalability and integration with third-party data sources, according to commentary in an AI drug discovery industry report dated 01/10/2025 on Evaluate Vantage as of 01/10/2025.

For investors in the United States, Schrodinger’s competitive position is also tied to broader sentiment toward high-growth, research-intensive companies on the Nasdaq. Periods of higher interest rates or risk aversion can weigh on valuations of unprofitable or less cash-generative biotech and software names, even when operational metrics such as customer count or pipeline progress are moving in a positive direction. As a result, the stock can experience meaningful swings around macroeconomic data, sector rotations and benchmark index moves, alongside company-specific news.

Why Schrodinger matters for US investors

For US-based investors, Schrodinger offers exposure to two themes that have drawn increasing attention on Wall Street: the digital transformation of pharmaceutical R&D and the application of AI to scientific discovery. As a Nasdaq-listed stock, SDGR can be included in growth-oriented portfolios, thematic strategies focused on healthcare innovation, and some AI-related exchange-traded funds, depending on index inclusion criteria, as referenced in ETF holdings data compiled on 11/05/2024 on a major ETF analytics platform Morningstar as of 11/05/2024.

The company’s revenue is primarily denominated in US dollars and a significant portion of its customer base and collaboration partners are located in the United States, which can make the stock relatively straightforward to analyze for domestic investors compared with companies heavily exposed to foreign exchange fluctuations. At the same time, Schrodinger does have global operations and international customers, so geopolitical developments, cross-border research collaborations and global regulatory changes can all influence its opportunity set and risk profile.

Another reason some US investors watch Schrodinger is its potential sensitivity to broader healthcare policy and drug pricing debates. While the company does not market approved drugs itself at this stage, the pace and scale of pharmaceutical R&D investment can be influenced by reimbursement policies, patent frameworks and government funding. Changes that materially alter pharma R&D budgets could indirectly impact demand for Schrodinger’s software tools and the willingness of partners to fund new discovery collaborations.

Conclusion

Schrodinger sits at a junction of software and biotechnology, aiming to use physics-based simulations and AI to improve drug discovery outcomes while monetizing its tools through recurring licenses and collaboration economics. Recent earnings reports underscore the divide between relatively steady software revenue and more variable drug discovery income, a pattern that can make quarterly comparisons noisy but also adds potential upside when milestones land. For US investors, the stock provides focused exposure to the digitalization of pharma R&D and to high-risk, high-reward early-stage discovery programs, yet it remains sensitive to sector sentiment, R&D spending cycles and the execution risk inherent in both software scaling and biotech pipelines.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.